Summary
IMvigor010 was a phase 3 randomised controlled trial evaluating adjuvant atezolizumab (a PD-L1 inhibitor) versus observation in patients with muscle-invasive urothelial carcinoma. The trial enrolled patients across multiple centres and assessed survival outcomes and safety. As suggested by the trial design and publication in The Lancet Oncology (2021), this represents a major clinical evaluation of checkpoint inhibitor efficacy in the adjuvant urothelial cancer setting.
UK applicability
The findings from this international multicentre trial would inform UK oncology practice and NICE guidance on adjuvant immunotherapy for urothelial cancer, though implementation would depend on NHS resource allocation and patient eligibility criteria.
Key measures
Disease-free survival, overall survival, safety and tolerability of adjuvant atezolizumab
Outcomes reported
The study assessed disease-free survival and overall survival outcomes in patients with muscle-invasive urothelial carcinoma receiving adjuvant atezolizumab compared to observation alone.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.